header image

Take a look through our annual reports.

How to contact us for media/press enquiries.

Have a comment or question? Get in touch.


Octapharma Introduces cutaquig® & IgCares™, Sponsors IDF National Conference


Patient Support Program Launched with New Therapy Provides Sustainability Initiative, Donations for PI Charities and Educational Resources

Octapharma USA: FDA Approves New Octaplas™ Product Label


New Labeling Reports Results of Post-Marketing Study Demonstrating Safety, Efficacy and Tolerability in Pediatric Patients

Octapharma Study Presented at CIS Demonstrates cutaquig® Efficacy and Safety


Research on Subcutaneous Immunoglobulin Reports Zero Serious Bacterial Infections

First New York City Screening of ‘Bombardier Blood’ Set for April 14th


Times Square Event Celebrating World Hemophilia Day Features Documentary on Chris Bombardier’s Quest to Climb the Seven Summits. New York City Hemophilia Chapter, Octapharma USA and Save One Life Partner for Free Screening, Q&A...

Octapharma Group reports strong results for 2018


Reporting revenue of €1.8 billion and operating income of €346 millionGroup sales increased 4.5% compared to 2017 (on a constant currency basis, the growth rate is 6.6%)All our products performed well, but to be highlighted are...